Patient Readiness to Provide Extensive Consent for Real-World Data in Rheumatology

Overview

This study evaluates the willingness of patients with inflammatory rheumatic diseases to grant broad consent for the secondary use of real-world data (RWD) within a secure data platform. The findings highlight the importance of patient consent in the governance of data platforms and the implications for future research and health policy.

Background

Real-world data (RWD) are increasingly recognized as vital for generating real-world evidence (RWE) that informs clinical research and health policy. The integration of RWD into healthcare systems can enhance understanding of treatment efficacy and safety in diverse patient populations. However, patient consent remains a critical factor in the ethical use of RWD, particularly under regulations like the GDPR.

Data Highlights

No numerical data available in the source material.

Key Findings

• Patients with inflammatory rheumatic diseases show varying levels of willingness to provide broad consent for secondary data use.
• Broad consent is essential for the effective governance of data platforms and the utilization of RWD in research.
• Regulatory frameworks, such as the GDPR, mandate informed consent for the reuse of RWD.
• Emerging European initiatives aim to harmonize the collection and use of high-quality RWD across borders.
• Patient autonomy and trust are fundamental to the acceptance of RWD-driven research.

Clinical Implications

Healthcare professionals must prioritize patient education regarding the use of RWD to foster trust and facilitate broad consent. Understanding patient perspectives on data sharing can inform the development of governance frameworks that align with ethical standards and regulatory requirements.

Conclusion

The study underscores the necessity of addressing patient concerns and preferences in the governance of RWD platforms to enhance the utility of real-world evidence in rheumatology and beyond.

Related Resources & Content

1. Drug Safety, 2025 -- Perspectives of Stakeholders on Utilizing Patient Registry Data for Pharmaceutical Decision-Making
2. Clinical Rheumatology, 2022 -- Characteristics of Patients and Utilization of Disease-Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis: An International Analysis
3. Drugs - Real World Outcomes, 2021 -- Overview, Obstacles, and Future Insights on Real-World Data and Evidence in Japan
4. Drug Safety, 2021 -- Gathering Information from Rare Disease Registries to Aid Regulatory Decisions: Insights from a Survey of Industry and Stakeholders
5. FDA, 2025 -- FDA Eliminates Major Barrier to Using Real-World Evidence in Drug and Device Application Reviews
6. American College of Rheumatology -- RISE FAQs
7. ScienceDirect -- Navigating real-world data sources in rheumatology: opportunities, pitfalls, and practical guidance
8. FDA Eliminates Major Barrier to Using Real-World Evidence in Drug and Device Application Reviews | FDA
9. RISE FAQs | American College of Rheumatology
10. Navigating real-world data sources in rheumatology: opportunities, pitfalls, and practical guidance - ScienceDirect